MedTrace Logo

Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea

NCT02183025 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 337

Last updated 2018-08-31

No results posted yet for this study

Summary

To access the efficacy and safety of Meloxicam 7.5 mg and 15 mg once daily compared with Mefenamic acid 500 mg t.i.d. over a treatment period of 3-5 days, during an observation period of 3 menstrual cycles, for the symptomatic relief of primary dysmenorrhea

Conditions

  • Dysmenorrhea

Interventions

DRUG

Meloxicam 7.5 mg

DRUG

Meloxicam 15 mg

DRUG

Mefenamic acid 500 mg

DRUG

Placebo matching 7.5 mg meloxicam

DRUG

Placebo matching 15 mg meloxicam

DRUG

Placebo matching 500 mg mefenamic acid

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-01-31
Primary Completion
1999-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02183025 on ClinicalTrials.gov